Biosurgery

The global bio surgery market should reach $8.3 billion and $12.5 billion in 2016 and 2021, respectively, growing at a five-year compound annual growth rate (CAGR) of 8.5%. The North American market should total $4.7 billion by 2021, up from $3.4 billion in 2016, demonstrating a five-year CAGR of 6.9%. The Asia-Pacific market should grow from $1.7 billion in 2016 to $3.0 billion by 2021 at a five-year CAGR of 11.1%.

The bio surgery products utilized globally in different surgical operations can be classified into anti-adhesive agents, haemostatic agents, surgical sealing agents, bone-graft substitutes, and soft tissue-management products, along with surgical synthetic and biological meshes. Among all products, bone-graft substitutes generate the most revenue, accounting for about $2.6 billion in 2015. This segment is expected to total $3.7 billion by 2021, growing at a five-year CAGR of 6.1% from 2016 to 2021. Surgical sealants products is projected as the fastest-growing segment among all markets with a five-year CAGR of 11% from 2016 to 2021, followed by the anti-adhesive agent segment with a five-year CAGR of 10.9%.